We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$247M
AUM Growth
+$69.9M
Cap. Flow
+$70.2M
Cap. Flow %
28.45%
Top 10 Hldgs %
43.11%
Holding
96
New
14
Increased
43
Reduced
12
Closed
25

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.72M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$6.46M
3
IMGN
Immunogen Inc
IMGN
+$5.37M
4
BLU
BELLUS Health Inc.
BLU
+$4.88M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.23M

Top Sells

Rank Stock Value
1
FULC icon
Fulcrum Therapeutics
FULC
+$5.24M
2
NXTC icon
NextCure
NXTC
+$3.68M
3
ARVN icon
Arvinas
ARVN
+$3.06M
4
INSM icon
Insmed
INSM
+$2.11M
5
ERAS icon
Erasca
ERAS
+$1.98M

Sector Composition

Rank Sector Weight
1 Healthcare 84.37%
2 Financials 5.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
26
United Therapeutics
UTHR
$26.1B
$3.14M 1.27%
14,551
-6,638
-31% -$1.3M
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.1B
$3.12M 1.27%
100,000
+80,568
+415% +$2.41M
HALO icon
28
Halozyme
HALO
$9.88B
$2.85M 1.16%
71,009
+10,839
+18% +$405K
INSM icon
29
Insmed
INSM
$22.4B
$2.74M 1.11%
100,621
-73,967
-42% -$2.11M
MCRB icon
30
Seres Therapeutics
MCRB
$45M
$2.67M 1.08%
16,030
+2,288
+17% +$364K
CYTK icon
31
Cytokinetics
CYTK
$10.6B
$2.65M 1.07%
58,190
+8,881
+18% +$343K
OTIC
32
DELISTED
Otonomy, Inc.
OTIC
$2.5M 1.01%
1,199,814
+182,766
+18% +$376K
VRDN icon
33
Viridian Therapeutics
VRDN
$2.2B
$2.45M 0.99%
123,806
+17,728
+17% +$330K
VRAY
34
DELISTED
ViewRay, Inc.
VRAY
$2.36M 0.96%
427,847
+242,812
+131% +$1.48M
AUPH icon
35
Aurinia Pharmaceuticals
AUPH
$1.95B
$2.29M 0.93%
+100,000
New +$2.37M
EYPT icon
36
EyePoint Inc
EYPT
$999M
$2.23M 0.9%
181,886
+52,596
+41% +$708K
SNDX icon
37
Syndax Pharmaceuticals
SNDX
$1.7B
$2.19M 0.89%
+100,000
New +$1.85M
STXS icon
38
Stereotaxis
STXS
$133M
$2.13M 0.86%
344,236
+52,540
+18% +$314K
JNCE
39
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.05M 0.83%
245,829
+37,270
+18% +$307K
BGMS
40
Bio Green Med Solution Inc
BGMS
$4.86M
$1.78M 0.72%
127
+19
+18% +$305K
CLDX icon
41
Celldex Therapeutics
CLDX
$2.94B
$1.74M 0.71%
45,132
+6,889
+18% +$300K
ASLN
42
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.68M 0.68%
+37,455
New +$2.25M
SGEN
43
DELISTED
Seagen Inc. Common Stock
SGEN
$1.68M 0.68%
10,848
-901
-8% -$151K
BBIO icon
44
BridgeBio Pharma
BBIO
$16.4B
$1.67M 0.68%
+100,000
New +$4.23M
PSTX
45
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1.6M 0.65%
+234,932
New +$1.6M
DCPH
46
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.57M 0.64%
160,526
+123,277
+331% +$2.32M
BNTC icon
47
Benitec Biopharma
BNTC
$414M
$1.54M 0.62%
34,559
+5,264
+18% +$294K
BIIB icon
48
Biogen
BIIB
$30.9B
$1.38M 0.56%
5,744
+1,355
+31% +$348K
ELOX
49
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$1.36M 0.55%
48,252
+16,756
+53% +$730K
MLTX icon
50
MoonLake Immunotherapeutics
MLTX
$1.56B
$1.3M 0.53%
131,823
-92,083
-41% -$915K
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Silverarc Capital Management held 96 positions worth $247M, up 40% from $177M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Silverarc Capital Management deployed $70.2M of net new capital in Q4 2021, opening 14 new positions and adding to 43 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was NextCure, an estimated $3.68M trimmed.

  • Silverarc Capital Management's largest Q4 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.
  • Silverarc Capital Management added most to Immunogen Inc in Q4 2021, an estimated $5.37M increase.
  • Silverarc Capital Management's biggest Q4 2021 reduction was NextCure, cutting an estimated $3.68M.
  • Silverarc Capital Management fully exited Fulcrum Therapeutics in Q4 2021, selling an estimated $5.24M.
  • Silverarc Capital Management's ten largest holdings make up 43% of its $247M portfolio in Q4 2021.
  • Silverarc Capital Management opened 14 new positions and closed 25 in Q4 2021.
  • Silverarc Capital Management's portfolio value rose 40% quarter-over-quarter to $247M.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.